Literature DB >> 34759201

Topical Nerve Growth Factor for the Treatment of Neurotrophic Keratopathy Caused by Wallenberg Syndrome.

Erika Mandarà1, Daniele Brocca2, Francesco Pellegrini3, Emanuela Interlandi4.   

Abstract

PURPOSE: The aim of this study was to report a case of central neurotrophic keratopathy (NK) in Wallenberg syndrome (WS) and its successful management with topical recombinant nerve growth factor (rNGF).
METHODS: A 47-year-old man with WS caused by a stroke in the territory of the left vertebrobasilar artery complained of progressive visual loss in his left eye (OS). Examination showed corneal anesthesia associated with a corneal epithelial ulceration consistent with a diagnosis of NK grade 3 of central origin. Topical treatment with rNGF, 1 drop 6 times daily, was started for 8 weeks, and the patient was followed up for 1 year.
RESULTS: Topical treatment with rNGF was successful in promoting complete epithelial corneal healing. No recurrence was seen at 1-year follow-up.
CONCLUSIONS: Clinicians should be aware that visual loss can also occur from NK of central origin. To the best of our knowledge, this is the first case report of NK caused by WS successfully treated with rNGF reported in the literature.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 34759201     DOI: 10.1097/ICO.0000000000002928

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  2 in total

1.  Neurotrophic Keratopathy in Systemic Diseases: A Case Series on Patients Treated With rh-NGF.

Authors:  Alessandro Meduri; Giovanni William Oliverio; Antonio Valastro; Claudia Azzaro; Umberto Camellin; Francesco Franchina; Leandro Inferrera; Anna Roszkowska; Pasquale Aragona
Journal:  Front Med (Lausanne)       Date:  2022-05-30

2.  Neurotrophic Keratopathy Treated with Topical Recombinant Human Nerve Growth Factor (Cenegermin): Case Series Study with Long-Term Follow-Up.

Authors:  Salvador García-Delpech; Patricia Udaondo; Alex Samir Fernández-Santodomingo; Damian García-Teillard
Journal:  Case Rep Ophthalmol       Date:  2022-08-31
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.